Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG

[1]  Q. Trinh,et al.  Construction of predictive models for recurrence and progression in >1000 patients with non‐muscle‐invasive bladder cancer (NMIBC) from a single centre , 2013, BJU international.

[2]  T. Cai,et al.  Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with inte , 2010, European urology.

[3]  T. D. de Reijke,et al.  Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladd , 2010, European urology.

[4]  L. Martínez-Piñeiro,et al.  Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. , 2009, The Journal of urology.

[5]  A. Papatsoris,et al.  Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy , 2009, Journal of Cancer Research and Clinical Oncology.

[6]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[7]  R. Dunn,et al.  Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. , 2007, Urology.

[8]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[9]  A. Orsola,et al.  Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. , 2005, European urology.

[10]  J. L. Sebastian,et al.  Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer , 2002, BJU international.

[11]  P. Schellhammer,et al.  Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. , 2002, The Journal of urology.

[12]  P. Sogani,et al.  Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? , 2001, The Journal of urology.

[13]  L. Kiemeney,et al.  Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. , 1998, Urology.

[14]  T. Lebret,et al.  Low-Dose BCG Instillations in the Treatment of Stage T1 Grade 3 Bladder Tumours: Recurrence, Progression and Success , 1998, European Urology.

[15]  A. Lembo,et al.  Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. , 1996, The Journal of urology.

[16]  W. Fair,et al.  Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Akaza,et al.  Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four‐year results , 1995 .

[18]  M. Babjuk,et al.  [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. , 2012, Actas urologicas espanolas.

[19]  M. Maffezzini.  Comment on: Predicting recurrence and progression in individual patients with stage ta T1 bladder cancer using eortc risk tables : A combined analysis of 2596 patients from seven eortc trials. eur urol 2006;49:466-77. by Richard J. Sylvester et al , 2006 .

[20]  H. Wallerand,et al.  The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. , 2001, The Journal of urology.

[21]  T. Lebret,et al.  Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. , 2000, The Journal of urology.

[22]  H. Akaza,et al.  Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. , 1995, Cancer.

[23]  V. Laudone,et al.  Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. , 1989, The Journal of urology.